- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Fingerpaint Acquires Managed Markets Firm 1798
Health and wellness marketing agency Fingerpaint (Saratoga Springs, NY) has acquired 1798, a market access and commercialization firm located in La Jolla, CA.
1798’s 60-person team specializes in developing tailored market access and commercialization support programs for drugs at any stage in the product life cycle. Fingerpaint founder Ed Mitzen commented: “With the acquisition of 1798, Fingerpaint will be able to assure our life sciences clients that we can provide the full continuum of market access planning and commercialization support services to successfully assist them in building their brands and launching new products.”
Terms of the deal were not disclosed.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
